

ALORNEY DOCKET NO. GC2047USw
Form PTO-1595

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

RECORDATION FORM COVER SHEET
PATENTS ONLY

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office Assignment Branch at (703) 306-5995 on Nov. 8, 2004 by Marilyn Eldridge

Sign: Marilyn Eldridge

Commissioner of Patents. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies)

Glaxo Wellcome Inc
7333 Mississauga Road North
Mississauga, Ontario
Canada L5N 6

2. Name and address of receiving party(ies)

GlaxoSmithKline Inc.
7333 Mississauga Road North
Mississauga, Ontario
Canada L5N 6L4

Additional names of conveying party(ies) attached?
 yes no

Additional name(s) and addresses attached?
 yes no

3. Description of the interest conveyed:

Assignment, please record and return
 Security Agreement
 Other: Amalgamation Recordation

Merger
 Change of Name

Execution date of Assignment: June 1, 2001

4. Application number(s) or patent number(s). Additional Sheets attached? Yes No

A. Patent Application No.(s)

B. Patent No.(s)
5,854,270

If this document is being filed together with a new application, the execution date of the application is

5. Name and address of party to whom correspondence concerning documents should be mailed:

Charles E. Dadswell
GlaxoSmithKline
Corporate Intellectual Property-MAI-B475
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398

6. Total number of applications and patents involved 1.

7. Total Fee (37 C.F.R. 3.41) \$40.00

8. Please charge this fee to deposit account No. 07-1392.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to our Deposit Account No. 07-1392.

DO NOT USE THIS SPACE

9. Statement and Signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Charles
Charles E. Dadswell
Reg. No. 35851

Charles
Signature

11/08/2004
Date

Total number of pages including cover sheet, attachments and document: 9

CH \$40.00 071392 5854270

GC2047USw

CERTIFICATE UNDER 37 C.F.R. §3.73(b)

Applicants: Renu Gambhir
Application No.: 08/817831
Patent No.: 5,854,270

Filed: 07/09/1997
Granted: 12/29/1998

For: Oral Compositions Containing Ondansetron
Glaxo Wellcome Inc. Corporation
(Name of Assignee) (Type of Assignee, e.g. corporation, partnership, university, etc.)

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. [] An assignment from the inventor(s) of the patent application identified above. The assignment was recorded on _____ in the Patent and Trademark Office at Reel _____, Frame _____, and for which a copy thereof is attached.

B. [X] A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: Renu Gambhir
To: Glaxo Wellcome Inc.

The document was recorded on 07/09/1997 in the Patent and Trademark Office at Reel 008640, Frame 0201, or which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or which a copy thereof is attached.


[X] Additional documents in the chain of title are listed here:
Certificate of Amalgamation and Articles of Amalgamation showing the amalgamation from Glaxo Wellcome Inc. to GlaxoSmithKline Inc. effective June 1, 2001, and a copy of which is attached

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is given below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 11/02/2004
GlaxoSmithKline Inc.
D/b/a GlaxoSmithKline.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Telephone No.: (919) 483-2370
Facsimile No.: (919) 483-7988

Signature: 
By: Charles E. Dadswell
Title: Attorney (resolution attached)

Power of Attorney

BY THIS POWER OF ATTORNEY given this 30th day of July two thousand and two, GlaxoSmithKline Inc., a Federal company amalgamated under the laws of Canada and having its registered office at 7333 Mississauga Road, North, Mississauga, Ontario, L4N 6L4 (hereinafter called "the Company"), **HEREBY** appoints all and any of its Directors, Secretary and Assistant Secretary for the time being and **DAVID ROBERTS, PETER JOHN GIDDINGS, ARTHUR WILLIAM RUSSELL TYRRELL, HUGH BAINFORDE DAWSON, BRIAN JOHN RUSSELL, DAVID MARTIN WATERS, HELEN QUILLIN, CHARLES KINZIG, STEPHEN VENETIANER, DAVID LEVY** and **CHARLES E. DADSWELL** jointly and severally to be its true and lawful agents and attorneys (hereinafter called "the Attorneys") on behalf and in the name of the Company or otherwise to do, perform, exercise or execute or concur with any other person or persons in doing, performing or exercising in or for any country or countries or jurisdiction in any part of the world all or any of the following powers, acts, deeds and things in connection with: letters patent, including extensions thereto; utility models; copyrights; trademark registrations; trademarks; trade names; trade dress; logos; design rights; designs and all rights analogous thereto and all applications therefor and any other forms whatsoever of intellectual property rights; including know-how, all of which are hereinafter called "Intellectual Property Rights", that is to say:

1. In any country or countries or jurisdiction in any part of the world to make application or cause application to be made for the grant or issue or transfer to the Company or registration in its name of Intellectual Property Rights and to take all steps necessary for the same to be prosecuted, maintained, withdrawn, renewed, enforced, defended or extended.
2. As the act and deed of the Company to sign, seal, deliver and execute all or any assignments or assurances, licences to the Company of or under any Intellectual Property Rights or the right to and interest in any inventions to be the subject of Intellectual Property Rights for the purpose of fully and effectually vesting and transferring the same in and to the Company.
3. As the act and deed of the Company to sign and execute all or any assignments and acceptances of the transfer or assignment of such rights, and also any licences, sub-licences and consents from the Company of or under any Intellectual Property Rights or the right to and interest in any invention to be the subject of Intellectual Property Rights, for the purpose of fully and effectually vesting transferring or granting the same in and to any entity, whether in the United Kingdom or elsewhere, in so far as such documents can be executed without the Company's seal being affixed thereto. For purposes of this Power of Attorney, the terms "entity" means, and includes, any person, firm or company or group of persons or unincorporated body.
4. To give undertakings or assurances to third parties and to any Trademark Registry or official intellectual property agency or governmental department or otherwise responsible for the registration or protection of trademarks, trade names, trade dress, logos, design rights or designs for the purpose of best protecting or ensuring the co-existence of the Company's rights to trademarks, trade names, trade dress, logos, design rights or designs.
5. To commence, prosecute and defend any proceedings or applications whether judicial or extra judicial relating to Intellectual Property Rights and to maintain, withdraw or settle the same.
6. For and in connection with any Intellectual Property Rights to sign, seal, deliver and execute any Power of Attorney or other deed or document authorising any agent, including trademark and patent agents and attorneys, to act on behalf of the Company.

PATENT

REEL: 015348 FRAME: 0347

- 7. To apply for the registration, amendment or cancellation of user rights in respect of any trademark or trade name.
- 8. To act in regard to all official communications which may now or hereafter be addressed to the Attorneys relating to Intellectual Property Rights or the renewal thereof in such manner that the Attorneys may be recognised as the authorised agent(s) of the Company in all proceedings in relation thereto.
- 9. For all or any of the purposes contained herein as the act and deed of the Company to sign, seal, deliver, execute and do all such documents, deeds, agreements, instruments and to do such acts as shall be requisite or may be deemed proper for or in relation to the said purposes.

AND THE COMPANY HEREBY RATIFIES and confirms and agrees to ratify and confirm all and whatsoever the Attorneys or any person, persons, firm or company appointed by them shall lawfully do or have done by virtue of the authorities herein contained


AND THE COMPANY HEREBY DECLARES that all instruments executed under and by virtue of this Power shall be as valid and effectual as if sealed by the Common Seal of the Company.

IN WITNESS whereof **GLAXOSMITHKLINE INC.** has caused its Common Seal to be hereunto affixed the day and year first before written

The **CORPORATE SEAL** of
GLAXOSMITHKLINE INC.
was hereto affixed in the presence of:

)
)
)


Corporate Secretary



COPY



Industrie Canada

**Certificate
of Amalgamation**

**Canada Business
Corporations Act**

**Certificat
de fusion**

**Loi canadienne sur
les sociétés par actions**

GLAXOSMITHKLINE INC.

390450-4

Name of corporation-Dénomination de la société

Corporation number-Numéro de la société

I hereby certify that the above-named corporation resulted from an amalgamation, under section 185 of the *Canada Business Corporations Act*, of the corporations set out in the attached articles of amalgamation.

Je certifie que la société susmentionnée est issue d'une fusion, en vertu de l'article 185 de la *Loi canadienne sur les sociétés par actions*, des sociétés dont les dénominations apparaissent dans les statuts de fusion ci-joints.

Director - Directeur

June 1, 2001 / le 1 juin 2001

Date of Amalgamation - Date de fusion

Canada




CANADA BUSINESS CORPORATIONS ACT	LOI RÉGISSANT LES SOCIÉTÉS PAR ACTIONS DE RÉGIME FÉDÉRAL
<p align="center">FORM 9 ARTICLES OF AMALGAMATION (SECTION 185)</p>	<p align="center">FORMULE 9 STATUTS DE FUSION (ARTICLE 185)</p>
<p>1. Name of amalgamated corporation</p> <p>GLAXOSMITHKLINE INC.</p>	<p>Dénomination de la société issue de la fusion</p>
<p>2. The place in Canada where the registered office is to be situated</p> <p>The City of Mississauga, In the Regional Municipality of Peel, Province of Ontario</p>	<p>Lieu au Canada où doit être situé le siège social</p>
<p>3. The classes and any maximum number of shares that the corporation is authorized to issue</p> <p>An unlimited number of one class of shares to be designated as common shares.</p>	<p>Catégories et tout nombre maximal d'actions que la société est autorisée à émettre</p>
<p>4. Restrictions, if any, on share transfers</p> <p>No share or shares in the capital of the Corporation shall be transferred without the consent of either (a) a majority of the directors of the Corporation expressed by a resolution passed at a meeting of the board of directors or by an instrument or instruments in writing signed by a majority of the directors, or (b) the holders of at least 51% of the outstanding voting shares of the Corporation expressed by a resolution passed at a meeting of such shareholders or by an instrument or instruments in writing signed by the holders of at least 51% of the outstanding voting shares of the Corporation.</p>	<p>Restrictions sur le transfert des actions, s'il y a lieu</p>
<p>5. Number (or minimum and maximum number) of directors</p> <p>Minimum of one (1) director; maximum of ten (10) directors</p>	<p>Nombre (ou nombre minimal et maximal) d'administrateurs</p>
<p>6. Restrictions, if any, on business the corporation may carry on</p> <p>None</p>	<p>Limites imposées à l'activité commerciale de la société, s'il y a lieu</p>
<p>7. Other provisions, if any</p> <p><u>Limitation on Number of Shareholders</u></p> <p>The number of shareholders of the Corporation, exclusive of persons who are in its employment and exclusive of persons who, having been formerly in the employment of the Corporation, were, while in that employment, and have continued after the termination of that employment to be, shareholders of the Corporation, is limited to 50, two or more persons who are the joint registered owners of one or more shares being counted as one shareholder.</p> <p><u>No Public Distribution</u></p> <p>Any invitation to the public to subscribe for securities of the Corporation is prohibited.</p> <p><u>Authorization to Appoint Additional Directors</u></p> <p>The directors may, within the maximum number permitted by the articles, appoint one or more directors, who shall hold office for a term expiring not later than the close of the next annual meeting of the shareholders, but the total number of directors so appointed may not exceed one-third of the number of directors elected at the previous annual meeting of shareholders.</p>	<p>Autres dispositions, s'il y a lieu</p>

NO. 9017 P. 5/7

8. The amalgamation has been approved pursuant to that section or subsection of the Act which is indicated as follows:

La fusion a été approuvée en accord avec l'article ou le paragraphe de la Loi indiqué ci-après

- sec 183 X
- : 184(1)
- : 184(2)


9. Name of the amalgamating corporations Dénomination des sociétés fusionnantes	Corporation No. N° de la société	Signature	Date	Title Titre
Glaxo Wellcome Inc.	390119-0		June 1, 2001	Corporate Secretary
SmithKline Beecham Inc.	333362-1		June 1, 2001	Corporate Secretary
FOR DEPARTMENTAL USE ONLY À L'USAGE DU MINISTÈRE SEULEMENT Corporation No. - N° de la société		Filed - Déposé 		


CANADA BUSINESS CORPORATIONS ACT

FORM 3 NOTICE OF REGISTERED OFFICE OR NOTICE OF CHANGE OF REGISTERED OFFICE (SECTION 19)

LOI RÉGISSANT LES SOCIÉTÉS PAR ACTIONS DE RÉGIME FÉDÉRAL

FORMULE 3 AVIS DU LIEU DU SIÈGE SOCIAL OU AVIS DE CHANGEMENT DU LIEU DU SIÈGE SOCIAL (ARTICLE 19)

1. Name of corporation - Dénomination de la société GLAXOSMITHKLINE INC.	2. Corporation No. - N ^o de la société
3. Place in Canada where the registered office is situated The City of Mississauga, in the Regional Municipality of Peel, Province of Ontario	Lieu au Canada où est situé le siège social
4. Address of registered office 7333 Mississauga Road North Mississauga, Ontario L5N 6L4	Adresse du siège social
CAUTION: Address of registered office must be within place specified in articles, otherwise an amendment is required (Form 4) in addition to this form. AVIS: L'adresse du siège social doit se situer à l'intérieur des limites du lieu indiqué dans les statuts. Sinon, une modification est requise (formule 4)	
5. Effective date of change Upon Amalgamation	Date d'entrée en vigueur du changement <div style="text-align: center; font-weight: bold; font-size: 1.5em;">FILED DÉPOSÉ</div>
6. Previous address of registered office Not Applicable	Adresse précédente du siège social
Date June 1, 2001	Signature 
Title - Titre Corporate Secretary	
Filed - Déposée	

CANADA BUSINESS CORPORATIONS ACT FORM 6 NOTICE OF DIRECTORS OR NOTICE OF CHANGE OF DIRECTORS (SECTIONS 106 AND 113)		LOI RÉGISSANT LES SOCIÉTÉS PAR ACTIONS DE RÉGIME FÉDÉRAL FORMULE 6 LISTE DES ADMINISTRATEURS OU AVIS DE CHANGEMENT DES ADMINISTRATEURS (ARTICLES 106 ET 113)	
1. Name of corporation - Dénomination de la société GLAXOSMITHKLINE INC.		2. Corporation No. - N° de la société	
3. The following persons became directors of this corporation:		Les personnes suivantes sont devenues administrateurs de la présente corporation:	
Name Nom	Effective date Date d'entrée en vigueur	Residential Address Adresse domiciliaire	Resident Canadian - Y/N Résident canadien - O/N
Paul N. Lucas	Upon Amalgamation	1055 Masters Green, Oakville, Ontario L6M 2N8	Yes
Kenneth Lendrum	Upon Amalgamation	26 Woodend Drive, Carlisle, Ontario L0R 1H0	Yes
Raymond Castonguay	Upon Amalgamation	558 Cochise Crescent, Mississauga, Ontario L5H 1Y2	Yes
Rod Wilson	Upon Amalgamation	1226 Priory Court, Oakville, Ontario L6M 1B7	Yes
4. The following person ceased to be a director of this corporation:		Les personnes suivantes ont cessé d'être administrateurs de la présente société	
Name Nom	Effective date Date d'entrée en vigueur	Residential Address - Adresse domiciliaire	
5. The directors of this corporation now are:		Les administrateurs de la présente société sont maintenant	
Name - Nom	Residential Address Adresse domiciliaire	Resident Canadian - Y/N Résident canadien - O/N	
Paul N. Lucas	1055 Masters Green, Oakville, Ontario L6M 2N8	Yes	
Kenneth Lendrum	26 Woodend Drive, Carlisle, Ontario L0R 1H0	Yes	
Raymond Castonguay	558 Cochise Crescent, Mississauga, Ontario L5H 1Y2	Yes	
Rod Wilson	1226 Priory Court, Oakville, Ontario L6M 1B7	Yes	
Date	Signature	Title - Titre	
June 1, 2001		Corporate Secretary	
		Filed - Déposé	